233 related articles for article (PubMed ID: 22429580)
1. [Clinical significance of T lymphocyte subset changes after first line chemotherapy in peripheral blood from patients with advanced stage adenocarcinoma cell lung cancer].
Yan X; Zhao X; Jiao S; Sun S; Wu L; Wu Z
Zhongguo Fei Ai Za Zhi; 2012 Mar; 15(3):164-71. PubMed ID: 22429580
[TBL] [Abstract][Full Text] [Related]
2. [Effect of Pembrolizumab on T Lymphocyte Subsets in Patients with Advanced
Non-small Cell Lung Cancer and Its Therapeutic Effect].
Wang Y; Wang Y; Jiang M; Zhao Y; Zhang X
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):182-187. PubMed ID: 33819968
[TBL] [Abstract][Full Text] [Related]
3. Detection of T lymphocyte subsets in the peripheral blood of patients with advanced lung adenocarcinoma.
Yan X; Zhao X; Jiao SC; Hu Y; Sun SJ; Wu LL; Wu ZY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2012 Jun; 34(3):234-8. PubMed ID: 22776655
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of docetaxol, pemetrexed and EGFR-TKIs as second-line treatment for patients with advanced non-small-cell lung cancer].
Zhang RX; Cai DY; Wu XH; Hua D
Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):869-72. PubMed ID: 23291140
[TBL] [Abstract][Full Text] [Related]
5. CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients.
Karagöz B; Bilgi O; Gümüs M; Erikçi AA; Sayan O; Türken O; Kandemir EG; Oztürk A; Yaylaci M
Med Oncol; 2010 Mar; 27(1):29-33. PubMed ID: 19148592
[TBL] [Abstract][Full Text] [Related]
6. Aberrant Alteration of Circulating Lymphocyte Subsets in Small Cell Lung Cancer Patients Treated with Radiotherapy.
Li H; Yu H; Lan S; Zhao D; Liu Y; Cheng Y
Technol Cancer Res Treat; 2021; 20():15330338211039948. PubMed ID: 34851203
[No Abstract] [Full Text] [Related]
7. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
8. Development and cross-validation of prognostic models to assess the treatment effect of cisplatin/pemetrexed chemotherapy in lung adenocarcinoma patients.
Mou W; Liu Z; Luo Y; Zou M; Ren C; Zhang C; Wen X; Wang Y; Tian Y
Med Oncol; 2014 Sep; 31(9):59. PubMed ID: 25119500
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of detecting peripheral blood T lymphocyte subsets in patients with pulmonary adenocarcinoma].
Zhao X; Yan X; Sun S; Wu Z; Jiao S
Nan Fang Yi Ke Da Xue Xue Bao; 2012 May; 32(5):752-4. PubMed ID: 22588942
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed versus docetaxel in second line non-small-cell lung cancer: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients.
Li R; Sun L; Wang J; Qian J; Wang Z; Jiao X
Pulm Pharmacol Ther; 2012 Oct; 25(5):364-70. PubMed ID: 22766314
[TBL] [Abstract][Full Text] [Related]
11. Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence.
Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
Anticancer Res; 2013 Aug; 33(8):3397-402. PubMed ID: 23898110
[TBL] [Abstract][Full Text] [Related]
12. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer.
Weiss GJ; Rosell R; Fossella F; Perry M; Stahel R; Barata F; Nguyen B; Paul S; McAndrews P; Hanna N; Kelly K; Bunn PA
Ann Oncol; 2007 Mar; 18(3):453-60. PubMed ID: 17322539
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma].
Zhang RX; Cai DY; Hong TT; Wu XH; Hua D
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):147-51. PubMed ID: 22780936
[TBL] [Abstract][Full Text] [Related]
14. [Predictive and prognostic value of monitoring lymphocyte subsets in peripheral blood before and after chemotherapy in patients with metastatic breast cancer].
Shao B; Li HP; DI LJ; Song GH; Jiang HF; Liang X; Wang CY; Yan Y; Lin XL; Wang LN; Wan FL; Yuan YH; You MN
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Apr; 48(2):304-9. PubMed ID: 27080286
[TBL] [Abstract][Full Text] [Related]
15. Changes in T-lymphocytes in lung cancer patients after hyperthermic intraperitoneal chemotherapy or radiotherapy.
Yan L; Wu M; Ba N; Shi G; Wang L; Zhang H
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323163
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY
Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719
[TBL] [Abstract][Full Text] [Related]
18. Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study.
Sun Y; Wu YL; Zhou CC; Zhang L; Zhang L; Liu XY; Yu SY; Jiang GL; Li K; Qin SK; Ma SL; Han L; Quinlivan M; Orlando M; Zhang XQ
Lung Cancer; 2013 Feb; 79(2):143-50. PubMed ID: 23182660
[TBL] [Abstract][Full Text] [Related]
19. Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy.
Murta EF; de Andrade JM; Falcão RP; Bighetti S
Tumori; 2000; 86(5):403-7. PubMed ID: 11130570
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
Rodrigues-Pereira J; Kim JH; Magallanes M; Lee DH; Wang J; Ganju V; Martínez-Barrera L; Barraclough H; van Kooten M; Orlando M
J Thorac Oncol; 2011 Nov; 6(11):1907-14. PubMed ID: 22005471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]